By Daniel Rosenberg Of DOW JONES NEWSWIRES CHICAGO -(Dow Jones)- Medtronic Inc. ( MDT) said Monday that its Endeavor III drug-eluting stent trial barely missed its main goal, and that secondary goals were met.
http://c.moreover.com/click/here.pl?r408966583
http://c.moreover.com/click/here.pl?r408966583